As Above, So Below
Page 1
As Above, So Below
ISBN: 9781370127580
Published by Richard Lawther
Copyright 2017 Richard Lawther
Thank you for downloading this ebook. This book remains the copyrighted property of the owner, and may not be redistributed to others for commercial or non-commercial purposes. If you enjoyed this book please encourage your friends to download their own copy from their favourite authorized retailer. Thank you for your support.
This book is a work of fiction, and except in the case of historical fact, any resemblance to actual persons living or dead is purely coincidental.
Thanks to Jeremy Sheldon and Jay S.
Cover image: Langdales, an oil painting by Jane Ward.
Contents
Prologue
One
Two
Three
Four
Five
Six
Seven
Eight
Intermission
Nine
Ten
Eleven
Twelve
Thirteen
Fourteen
Fifteen
Sixteen
Seventeen
Eighteen
Nineteen
Twenty
Twenty-one
Twenty-two
Twenty-three
Twenty-four
Twenty-five
Twenty-six
Twenty-seven
Twenty-eight
Twenty-nine
Author’s notes
Prologue
Utah State University.
Biochemistry Dept, Professor Meyer’s office.
May 2.
‘Hello? ... Oh yeah, send him in.’
Professor Eric Meyer glanced up as his colleague, Dr. William Layton, entered the room. Layton placed his briefcase on Meyer’s desk and clicked it open. ‘Morning, Eric, I’ve got the first study results on DK61-12–’ He handed Meyer a large file, ‘–they’re kinda disappointing.’
‘Disappointing?’ Meyer flicked through the file, stopping briefly to study some of the pages before dropping it down on his desk. ‘How the hell can they be disappointing!? This was going to be the big breakthrough, we both thought that.’
Layton gave a slight shrug. ‘Well, it still could be, Eric, but not in the way we expected.’
Meyer and Layton had been conducting preclinical trials on the newly discovered ketamine derivative: DK61-12. Like the parent drug, it acted as both stimulant and anaesthetic, but, crucially, DK61-12 did not exhibit ketamine’s unwanted dissociative properties.
The initial trials on animals had been very encouraging: all the animals tested remained highly alert and each acquired a considerable insensitivity to pain. The drug’s toxic side-effects were minor, only manifesting themselves after absurdly high doses, and no behavioural problems were observed – even after prolonged use.
DK61-12 looked set to be a pharmacological goldmine. From postoperative to battlefield treatment, the urgent need for a reliable and safe stimulant painkiller would help to underpin the drug’s clinical future.
The Food and Drugs Administration had readily sanctioned the commencement of phase I human trials, and the pharmaceutical company that owned the patent to the drug had again selected Meyer and his team to begin this potentially lucrative work. The first human test results were covered in the report splayed out on Meyer’s desk.
‘Okay then, Bill, bring me up to speed.’
‘Right. Well, as you recall we decided on a suitable dose based on the chimp results. We adjusted for human bodyweight and then, to play it safe, we reduced that dose by fifty percent...’
Meyer nodded and waited for Layton to continue.
‘The subject was a sophomore volunteer called South. We hooked him up to the pain-standard and EEG, and then administered the dose via intramuscular injection. By this method the drug hit his brain within fifteen to twenty seconds–’
‘How many were present at this?’ interrupted Meyer.
‘Excluding the subject and myself, there were four others: two support staff and two physicians. Anyway, after about thirty seconds South’s EEG went right off the scale – but it only lasted for a few seconds. By the time any of us had a chance to examine him, the indicators had returned to normal, and he seemed to be perfectly relaxed. There were no further signs of contraindication so, after about three minutes, I began asking him some simple questions: was he feeling okay, comfortable – you know, general stuff.’
‘And?’ prompted Meyer.
‘He looked at me, but he didn’t say a word.’ Layton shook his head.
‘Was he high? Why didn’t he–’
‘No he wasn’t high. He was alert and he didn’t seem to be in any distress; he wasn’t bothered by the pain-standard, but then we expected that. He just refused to speak. At first we thought he was just indulging in some kind of prank; the drug dose was low and we weren’t expecting anything other than stimulated pain suppression... look, it’s all in that report there.’ Layton pointed to the fat file on Meyer’s desk.
‘Yes I know it’s in the damn report! I’ll be reading that later. Continue please.’
Layton sighed: ‘There were no further developments during the trial. South remained attentive and apparently happy; we offered him a glass of water and he drank from it readily.’
‘But he didn’t communicate with you,’ added Meyer.
‘Not a word. We continued to suspect South was playacting; he had a reputation for practical jokes – I mean he has a reputation... Anyhow, fifty minutes later, as the drug’s effect wore off, South spoke for the first time.’
‘What did–?’
‘Nothing much, he just complained about the pain-standard. Naturally, I wanted to know why he hadn’t been speaking to us, but South was having difficulty making sense of the previous hour.’
‘Does DK61-12 have an amnesiac effect?’
‘No, not as far as we can tell.’
‘So what the hell was going on then?’
‘I admit, at the time it did look like amnesia, but it probably wasn’t. It turned out that South could remember certain events that took place during the experiment; he could recall images of being handed the water, and he remembered drinking it and enjoying it. Apart from that, he couldn’t remember anything much; he was unable to recall any conversations.’
‘What!? ...But you were asking him questions for God’s sake; and the others, they must have been jabbering away in the background – pouring over the readouts.’
‘Well, yeah, but not according to South. I guess I was just plain baffled at this point, so I dismissed the subject. The next day I called him into my office and we went over the details of the experiment and his comments afterwards. South stated that during the experiment he was generally bored and, once again, that he couldn’t recollect a single spoken word.’ Layton paused and waited for Meyer to take all of this in.
Eventually Meyer chipped in: ‘This all took place, let’s see, just over three weeks ago?’ He looked at Layton, who nodded. ‘And you say South is fine – one hundred percent?’
‘Yes, he’s fine.’
‘Jeez! I hope so, you didn’t give him any more DK, did you?’
‘No! and relax, Eric, South’s okay – he is his normal, confident, mildly arrogant, self.’
‘Alright then, Bill, but what happened, and why did none of this show up in the animal trials?’
Layton retrieved his report from Meyer’s desk and began to search for a particular section. On finding it, he continued with his briefing: ‘We took a series of blood and urine samples from South; these demonstrated that the drug was fully broken down, along with its by-products, after about 7 to 8 days
– just like ketamine. As for South’s behaviour: we isolated a neurotransmitter analogue from his blood. It looks like it’s part of the administered DK61 chain. It’s a good match for a receptor found in the human brain, and only the human brain – receptor Pg101.’
‘Pg101? I haven’t heard of that one.’
‘It’s only newly discovered. It’s found in the dominant temporal lobe, more specifically, in Wernicke’s area – the area most responsible for comprehending received speech and selecting words to express ideas.’ Layton paused, then continued: ‘It seems that South’s language processor got shut down. Despite this, he remained alert and probably suffered no cognitive deficit beyond the fact that he couldn’t understand language, any language, or even the concept of language. It’s no wonder South had difficulty remembering anything from his period ‘under’, he was thinking in a very odd and wordless manner. His mind must have been profoundly changed.’
‘H Christ!!’ exclaimed Meyer. ‘That’s our research well and truly screwed!’ He held his head in his hands.
‘Come on, Eric, I think this is very interesting–’
‘Interesting!? Try telling that to the FDA!’
Layton remained silent.
‘Take the results of the human and animal trials and prepare to get them published. Then dump the work, I don’t want anything more to do with it – and do not give DK to any more human subjects! That’s all.’
Meyer had finished and Layton gratefully took his cue to leave. The briefing with his boss had gone much as he’d expected: Meyer and his important cohorts in the pharma’ industry were only ever interested in commercial gain: the DK61-12 results were too strange and too unprofitable to be of interest.
Layton left Meyer to beat ectopically upon his bald top.
But aspects of the South case remained hidden from both Layton and Meyer:
With the sudden disappearance of language, South’s mind had found itself confronted by a gaping void in its consciousness – was there any consciousness at all? South’s mind didn’t know, it couldn’t even phrase the question. In its panicked state the cerebral cortex attempted to locate an alternative to the language processor, something that might return a coherence to the brain’s functioning. There was a candidate.
As the cortex fired in random chaos, another DK61-12 neurotransmitter analogue attempted to take up residence at receptor sites on the thalamus, located deep within the brain. This fact remained unknown to Layton and Meyer since the sites in question were obsolete and no studies had revealed their presence.
The analogue, a poor fit, would have had no effect on its own, but as the cortex panicked it triggered a massive surge of electrical activity in all parts of the brain. Dormant connections between the cerebral cortex and thalamus flared into life and the DK61-12 analogue forced itself home. To stay. For the first time in countless millennia, the thalamus turned on its antenna.
Since the evolution of the cerebrum, the thalamus has played a wholly subordinate role. Its main purpose is to serve as the brain’s relay station, but its largest nucleus has a crude awareness of its own. It is able to understand subconscious sensations.
Less than one minute after South received DK61-12 his brain returned to stable equilibrium. The cerebral cortex learnt to function without language, but the thalamus grew curious about its recently rediscovered part. Unbeknown to the conscious mind, it attempted some simple transmissions. If translation were possible, South’s thalamus broadcast something like:
‘It’s me!!’
‘Listen to meeeeeee!!!!’
Nobody did. No human brain could receive this broadcast.
South’s thalamus continued to make transmissions but, disenchanted with the vast silence it received in return, it ultimately gave up. The antenna became forgotten over time, but it remained switched on. Should anyone make a broadcast, something in South would hear it.
Ten years later.
1